Aurobindo Pharma posts net profit of Rs 92 cr in Q3

The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal

today posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets.

The Hyderabad-based firm had posted a of Rs 28.54 crore for the corresponding period of previous fiscal.   

Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.

"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.

He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.

"These will pave the way for consolidating injectable formulations business," Govindarajan added.

The company said its board also approved an of 100%, Re 1 per equity share of Re 1 for the year 2012-13.

Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07% from their previous close.

image
Business Standard
177 22
Business Standard

Aurobindo Pharma posts net profit of Rs 92 cr in Q3

The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal

Press Trust of India  |  New Delhi 



today posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets.

The Hyderabad-based firm had posted a of Rs 28.54 crore for the corresponding period of previous fiscal.   


Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.

"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.

He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.

"These will pave the way for consolidating injectable formulations business," Govindarajan added.

The company said its board also approved an of 100%, Re 1 per equity share of Re 1 for the year 2012-13.

Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07% from their previous close.

RECOMMENDED FOR YOU

Aurobindo Pharma posts net profit of Rs 92 cr in Q3

The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal

Aurobindo Pharma today posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets
today posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets.

The Hyderabad-based firm had posted a of Rs 28.54 crore for the corresponding period of previous fiscal.   

Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.

"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.

He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.

"These will pave the way for consolidating injectable formulations business," Govindarajan added.

The company said its board also approved an of 100%, Re 1 per equity share of Re 1 for the year 2012-13.

Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07% from their previous close.
image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard